FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia
eMediNexus, 30 March 2018
remove_red_eye 1693 Views
#Hematology #Nursing #Oncology #Pathology and Lab Medicine
remove_red_eye 1693 Views
#Hematology #Nursing #Oncology #Pathology and Lab Medicine
The US FDA has expanded the approval of blinatumomab (Blincyto) to include the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), for patients in remission who still have minimal residual disease (MRD).
To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
